focus -WSS

focus

author：focus 2025-09-30 16:24:40 - browse：99627

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Male doctors called my cancer incurable. A female doctor showed it wasn't

WSS

Does good food count as health care? Study aims to find out

Gene therapy denied for Afghan refugee whose father aided U.S.

Medicare Advantage coverage denials need scrutiny, senators say

FDA early review: GLP

Wegovy, Zepbound and weight loss drugs that preserve muscle

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

hotspot

focus

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

Poor hospice wound care hurts patients and families

ChatGPT in medicine: STAT answers readers' burning questions

Why medical students are struggling with mental health

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Nonprofit, backed by Microsoft, to certify AI tools in health care

BioMarin wins approval for gene therapy to treat hemophilia A

Boston Scientific acquires urology company Axonics for $3.7 billion

United colonoscopy coverage change 'may cost lives,' doctors say

Arena BioWorks launches in Cambridge to speed drug discovery

knowledge

Arena BioWorks launches in Cambridge to speed drug discovery

Does good food count as health care? Study aims to find out

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

American taxpayers paid $1.8 trillion in health care costs in 2022

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

FDA's Woodcock to retire early next year

hotspot

hotspot

explore

hotspot